HighTower Advisors LLC Has $2.40 Million Position in DaVita Inc. (NYSE:DVA)

HighTower Advisors LLC decreased its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 31.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,037 shares of the company's stock after selling 7,298 shares during the quarter. HighTower Advisors LLC's holdings in DaVita were worth $2,398,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Amundi increased its stake in DaVita by 116.4% during the 4th quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after buying an additional 240,126 shares during the period. FMR LLC boosted its stake in DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company's stock worth $29,082,000 after purchasing an additional 154,061 shares during the period. Glenmede Trust Co. NA grew its holdings in shares of DaVita by 731.6% during the third quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company's stock valued at $20,207,000 after buying an additional 108,446 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of DaVita by 17.8% during the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock worth $99,846,000 after purchasing an additional 92,014 shares during the period. Finally, Strategic Financial Concepts LLC purchased a new position in shares of DaVita during the 4th quarter valued at $9,371,000. Institutional investors own 90.12% of the company's stock.

DaVita Trading Up 0.3 %

Shares of NYSE DVA traded up $0.52 during mid-day trading on Wednesday, hitting $151.30. The company's stock had a trading volume of 573,822 shares, compared to its average volume of 783,521. The company's fifty day simple moving average is $158.18 and its 200-day simple moving average is $157.57. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a one year low of $125.64 and a one year high of $179.60. The stock has a market cap of $12.10 billion, a price-to-earnings ratio of 14.09, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99.

Remove Ads

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, sell-side analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Cowen restated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on DaVita in a research report on Friday, February 21st. Barclays lifted their target price on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Finally, StockNews.com lowered shares of DaVita from a "buy" rating to a "hold" rating in a report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.